An overview of the diagnostic work-up and treatment options offered to a 76-year-old male with castrate-sensitive prostate cancer who experiences recurrence.
Videos
Nicholas Vogelzang, MD, FASCO, FACP, comments on managing an elderly patient with hormone-sensitive prostate cancer with apalutamide and ADT based on data demonstrated by the phase 3 TITAN trial.
Kartik Konduri, MD, comments on the future of treating extensive-stage small cell lung cancer and provides advice for community oncologists treating patients with the disease.
Kartik Konduri, MD, describes the phase 2 basket trial of lurbinectedin in the treatment of extensive-stage small cell lung cancer.
Kartik Konduri, MD, discusses treatment options for extensive-stage small cell lung cancer.
Kartik Konduri, MD, evaluates the case of a 68-year-old woman with extensive-stage small cell lung cancer.
Kartik Konduri, MD, reviews the case of a 68-year-old woman with small-cell lung cancer.
Ulka N. Vaishampayan, MBBS, FAB, discusses the updated data from CheckMate 214 of nivolumab and ipilimumab versus sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma.
Nicholas Rohs, MD, of Mount Sinai Hospital discusses the importance of genetic testing in lung cancers that harbor KRAS and EGFR mutations.
Marcia Brose, MD, PhD discusses the key unanswered questions oncologists have for treating patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer.
Jeff Patton, MD, explains the importance of preparedness in community oncology clinics as a World Cancer Day note.
Ken Kato, MD discusses the outcomes of the phase 3 KEYNOTE-590 study on esophageal cancer.
Brendon Stiles, MD, discusses the current landscape for treating patients with metastatic lung cancer.
Final analysis of data on HER2-positive disease presented at the 2020 San Antonio Breast Cancer Symposium from experts in the field of breast oncology.
Experts in breast oncology discuss the evolving role of trastuzumab deruxtecan for metastatic HER2-positive breast cancer.
Hatem Soliman, MD, reviews statistically significant data from the PERTAIN study, presented at the 2020 San Antonio Breast Cancer Symposium.
Hang Quach, MBBS(Hons), SpecCertOC, FRACP, FRCPA, MD, talks about the use of carfilzomib, dexamethasone, and daratumumab as a cheaper alternative for treating relapsed or refractory multiple myeloma as seen in the ALLG MM018/ AMN002 study.
Danielle Hammond, MD, discusses the results from a retrospective review of patients with acute myeloid leukemia treated over the last 6 years with a combination of venetoclax and either decitabine or azacitadine.
Luis E. Raez, MD, discusses the treatment of TRK fusion-positive lung cancers in the past and the present.
Experts in breast oncology discuss their real-world experience with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer.
Analysis from the ALTTO (BIG 2-06) trial and the relationship between a short or long disease-free interval and overall survival.
Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.
Updated findings on the use of neratinib for HER2+ breast cancer from the 2020 SABCS Virtual Symposium.
A discussion on the importance of prognostic tools for early stage breast cancer.
Hatem Soliman, MD, discusses data presented at the 2020 SABCS for patients with HER2-enriched subtypes that showed benefit from CDK4/6 inhibition.
Andrew Seidman, MD, provides insight on clinical sequencing for patients with advanced HER2-positive breast cancer.
Experts in breast oncology discuss the evolving landscape in early stage and metastatic HER2-positive breast cancer.